NORTHWEST BIOTHERAPEUTICS INC Deferred Tax Assets, in Process Research and Development
NORTHWEST BIOTHERAPEUTICS INC (NWBO) had Deferred Tax Assets, in Process Research and Development of $24.84 million as of 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-04-15
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $24.84M.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $23.50M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $15.82M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $9.14M.
| Period end | Deferred Tax Assets, in Process Research and Development | Deferred Tax Assets, in Process Research and Development as first filed |
|---|---|---|
| 2025-12-31 | $24.84M 10-K · filed 2026-04-15 | |
| 2024-12-31 | $23.50M 10-K · filed 2026-04-15 | |
| 2023-12-31 | $15.82M 10-K · filed 2025-03-31 | |
| 2022-12-31 | $9.14M 10-K · filed 2024-03-05 | |
| 2021-12-31 | $17.98M 10-K · filed 2022-03-01 | |
| 2020-12-31 | $18.58M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $16.98M 10-K · filed 2021-03-31 | |
| 2018-12-31 | $16.38M 10-K · filed 2020-03-16 | |
| 2017-12-31 | $15.43M 10-K · filed 2019-04-02 | |
| 2016-12-31 | $14.91M 10-K · filed 2018-04-17 | |
| 2015-12-31 | $12.66M 10-K · filed 2017-04-17 | |
| 2014-12-31 | $9.91M 10-K · filed 2016-03-16 | |
| 2013-12-31 | $4.05M 10-K · filed 2015-03-17 | $4.05K 10-K · filed 2014-04-01 |
| 2012-12-31 | $3.75K 10-K · filed 2014-04-01 | $3.57M 10-K · filed 2013-04-08 |
| 2011-12-31 | $3.27M 10-K · filed 2013-04-08 |